JPRN-UMIN000048841已完成Unknown
Therapeutic Effects of Clarithromycin Combined with Molnupiravir in Management of Mild to Moderate COVID-19 Hospitalized Patients: a case control study - Therapeutic Effects of Clarithromycin Combined with Molnupiravir in Management of Mild to Moderate COVID-19 Hospitalized Patients
Daido Central Hospital0 个研究点目标入组 119 人开始时间: 2022年12月31日最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 119
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 3days-old 至 5days-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •not Mild or moderate patient
研究者
相似试验
已完成
不适用
Study assessing combined therapy with clarithromycin and amoxicillin in childhood acute otitis mediaPediatric patients with childhood acute otitis media determined to be of moderate severity in accordance with the Clinical Practice Guideline for Diagnosis and Management of Acute Otitis Media in Children (2013, hereinafter referred to as the Guideline).JPRN-UMIN000015564Wakayama Medical University otolaryngology, head and neck surgery210
已完成
不适用
The pharmacokinetic effect of clarithromycin on the AUC0-12h of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patientstuberculosis10028440TBNL-OMON35904niversitair Medisch Centrum Groningen7
进行中（未招募）
不适用
The effect of combining two anti-tuberculosis drugs, clarithromycin and linezolid, on the amount of clarithromycin and linezolid in the blood of severe tuberculosis patients.Multidrug-resistant and extensively drug-resistant tubeculosis (MDR/XDR-TB)MedDRA version: 14.0Level: LLTClassification code 10043148Term: TBSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-000513-39-NLniversity Medical Center Groningen8
已完成
不适用
Comparison of two different treatment regimens for treatment of leprosy.CTRI/2022/08/045078S Nijalingappa Medical College and HSK Hospital and Research centre40
已完成
不适用
Impact of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci among healthy volunteers: a randomised, double-blind, placebo-controlled trialISRCTN26642689Abbott Pharmaceuticals (Belgium)203